News

A new chemical entity, ENMD-1198 is based on a modified chemical structure of 2-methoxyestradiol (2ME2) and is designed to decrease metabolism while retaining 2ME2’s multiple mechanisms of action.

ZIO-101, a novel organic arsenic, has demonstrated safety at doses approximately 25 times higher than the currently approved dose for arsenic trioxide, an inorganic arsenic currently approved for

The three separate studies of Modrenal (trilostane) will investigate the efficacy of the treatment in three distinct settings: a phase IV trial in advanced, post-menopausal breast cancer; a

The study demonstrated that the addition of the drug to radiation resulted in a 9.5 month improvement in median duration of locoregional control, or the prevention of the

The phase II trial in patients with non-small cell lung cancer (NSCLC) evaluating BLP25 Liposome Vaccine (L-BLP25) showed that the new formulation of the vaccine is not different

The findings build on previous study results showing that Actos, an oral anti-diabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16% in

The researchers investigated the benefits of using a patient’s own (autologous) selected adult stem cells, called CD34+ cells, to treat coronary artery disease. A total of 24 patients

State Food and Drug Administration (SFDA) has approved H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory

The vaccine candidate uses the Adenovirus-35 vector technology and expresses HIV-1 antigens. Building on Transgene’s viral vectors manufacturing processes and long experience in the field, two vaccine batches